IP Library Granted Patent US 9,011,477
Granted Patent B2
US 9,011,477 · App. 14/270,272 · Granted Apr 21, 2015

Intragastric device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,011,477
App. No.
14/270,272
Granted
Apr 21, 2015
Kind
B2
Abstract

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Claims (27)

1. An intragastric balloon comprising:

an initial fill gas, consisting of nitrogen and one or more inert gases selected from the group consisting of SF 6 , C 2 F 6 , C 3 F 8 , C 4 F 10 , C 4 F 8 , C 3 F 6 , CF 4 , and C(ClF 2 )—CF 3 ;

a valve system configured for introducing the initial fill gas into the balloon in vivo; and

a polymeric wall comprising one or more layers, wherein the polymeric wall is configured to have, under in vivo conditions, a permeability to CO 2 of more than 10 cc/m 2 /day, and wherein the polymeric wall is configured such that, in vivo, the balloon is configured to gain in volume and in pressure during a useful life of the intragastric balloon when filled with the initial fill gas,

wherein the intragastric balloon when inflated with the initial fill as is ellipsoid with a nominal radius of from 2.5 cm to 7.6 cm, a nominal height of from 0.6 cm to 7.6 cm, a volume of from 90 cm 3 to 350 cm 3 at 37° C., an internal nominal pressure at 37° C. of 0 Pa to 103421 Pa, and a weight of less than 15 g.

2. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a three layer CO 2 barrier material consisting of nylon/polyvinylidene chloride/polyethylene.

3. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a three layer CO 2 barrier material consisting of nylon/ethylene vinyl alcohol/polyethylene.

4. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a two layer CO 2 barrier material consisting of nylon/polyethylene and no additional CO 2 barrier material.

5. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a four layer CO 2 barrier material consisting of nylon/ethylene vinyl alcohol/polyvinylchloride/polyethylene.

6. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a nylon layer, a polyvinylidene chloride layer, and a polyethylene layer.

7. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a nylon layer, a polyvinylidene chloride layer, a polyethylene layer, and an ethylene vinyl alcohol layer.

8. The intragastric balloon of claim 1 , wherein the polymeric wall comprises a nylon layer, a polyethylene layer, and an ethylene vinyl alcohol layer.

9. The intragastric balloon of claim 1 , wherein the inert gas initial fill gas consists of nitrogen and SF 6 .

10. The intragastric balloon of claim 1 , wherein the intragastric balloon is configured to have a useful life in an in vivo gastric environment of at least 30 days and wherein the balloon wins from 5 to 300% in volume during the useful life of the intragastric balloon when filled with the initial fill gas.

11. A method for inflating an intragastric balloon, comprising:

providing an intragastric balloon comprising a valve system and a polymeric wall, wherein the polymeric wall comprises one or more layers, and wherein the polymeric wall is configured to have, under in vivo conditions, a permeability to CO 2 of more than 10 cc/m 2 /day;

introducing, in an in vivo intragastric environment, an initial fill gas consisting of nitrogen and one or more inert gases selected from the group consisting of SF 6 , C 2 F 6 , C 3 F 8 , C 4 F 10 , C 4 F 8 , C 3 F 6 , CF 4 , and C(ClF 2 )—CF 3 into the intragastric balloon through the valve system so as to fill the intragastric balloon, wherein the filled balloon is ellipsoid with a nominal radius of from 2.5 cm to 7.6 cm, a nominal height of from 0.6 cm to 7.6 cm, an initial volume of from 90 cm 3 to 350 cm 3 at 37° C., an internal nominal pressure at 37° C. of 0 Pa to 103421 Pa, and a weight of less than 15 g; and

exposing the filled balloon to the in vivo intragastric environment for a useful life of the intragastric balloon, whereby the initial fill gas diffuses through the polymeric wall and into the in vivo intragastric environment, and whereby gases in the in vivo intragastric environment diffuse into the balloon through the wall, whereby the intragastric balloon gains in volume and in pressure over the useful life.

12. The method of claim 11 , wherein the polymeric wall comprises a three layer CO 2 barrier material consisting of nylon/polyvinylidene chloride/polyethylene.

13. The method of claim 11 , wherein the polymeric wall comprises a three layer CO 2 barrier material consisting of nylon/ethylene vinyl alcohol/polyethylene.

14. The method of claim 11 , wherein the polymeric wall comprises a two layer CO 2 barrier material consisting of nylon/polyethylene and no additional CO 2 barrier material.

15. The method of claim 11 , wherein the polymeric wall comprises a four layer CO 2 barrier material consisting of nylon/ethylene vinyl alcohol/polyvinylchloride/polyethylene.

16. The method of claim 11 , wherein the polymeric wall comprises a nylon layer, a polyvinylidene chloride layer, and a polyethylene layer.

17. The method of claim 11 , wherein the polymeric wall comprises a nylon layer, a polyvinylidene chloride layer, a polyethylene layer, and an ethylene vinyl alcohol layer.

18. The method of claim 11 , wherein the polymeric wall comprises a nylon layer, a polyethylene layer, and an ethylene vinyl alcohol layer.

19. The method of claim 11 , wherein the initial fill gas consists essentially of nitrogen and SF 6 .

20. The method of claim 11 , wherein the intragastric balloon is configured to have a useful life in an in vivo gastric environment of at least 30 days, and wherein the balloon gains from 5 to 300% in volume during the useful life of the intragastric balloon when filled with the initial fill gas.

Assignments (3)
SECURITY INTEREST Recorded Oct 24, 2024
From: RESHAPE LIFESCIENCES INC.
To: ASCENT PARTNERS FUND LLC
Reel/Frame 070166/0882 →
CHANGE OF NAME Recorded Oct 6, 2021
From: OBALON THERAPEUTICS, INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 057726/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2014
From: BRISTER, MARK C.; RASDAL, ANDREW P.; DRAKE, NEIL R.; LAKE, MATTHEW S.; MARKOVIC, DUBRAVKA; VANDENBERG, AMY D.L.; LLEVARES, ANTONIO C.; NIDER, JOSEFINA
To: OBALON THERAPEUTICS, INC.
Reel/Frame 033877/0181 →